You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | n/a |
| Div Cover | n/a | n/a |
| Op Mrgn | 0.0% | n/a |
| ROCE | 19.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -107.0 | n/a |
| PEG | 0.0 | n/a |
| Price / Revenue | 0.0 | n/a |
| Price / Book value | 11.7 |
| Latest | Forecast | |
|---|---|---|
| Revenue | n/a | 0.0% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | 0.0% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2018-04-30 | n/a | -4.94 | -1.31p | -9.1 | 0.0 | n/a | n/a | 0.0% |
| 2019-04-30 | n/a | -6.71 | -1.42p | -3.6 | 0.0 | n/a | n/a | 0.0% |
| 2020-04-30 | n/a | -6.77 | -1.18p | -6.7 | 0.0 | n/a | n/a | 0.0% |
| 2021-04-30 | n/a | -16.81 | -2.28p | -9.6 | 0.0 | n/a | n/a | 0.0% |
| 2022-04-30 | n/a | -3.77 | -0.25p | -57.0 | 0.0 | n/a | n/a | 0.0% |
| Scancell licenses Vaccitech IP for its next vaccine candidate Sharecast News | 07 Nov |
|---|---|
| Scancell enrols and doses first patient in latest cancer trial Sharecast News | 31 Oct |
| Scancell losses widen on expense of ongoing trials Sharecast News | 28 Oct |
| Second Price Monitoring Extn | 06-Dec-22 23:58 |
|---|---|
| Price Monitoring Extension | 06-Dec-22 23:58 |
| Result of Annual General Meeting | 21-Nov-22 23:59 |
| Licenses Vaccitech technology to advance Modi-2 | 07-Nov-22 14:16 |
| First patient dosed in expansion phase of ModiFY | 31-Oct-22 15:01 |